Cargando…
Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis
BACKGROUND: Inexpensive medicines with a long history of use may currently be prescribed off-label for rare indications. Reimbursement is at the discretion of health insurance companies, and may be unpredictable. The example addressed was ephedrine as add-on treatment for myasthenia gravis. Stakehol...
Autores principales: | Weinreich, Stephanie S., Vrinten, Charlotte, Kuijpers, Marja R., Lipka, Alexander F., Schimmel, Kirsten J. M., van Zwet, Erik W., Gispen-de Wied, Christine, Hekster, Yechiel A., Verschuuren, Jan J. G. M., Cornel, Martina C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427624/ https://www.ncbi.nlm.nih.gov/pubmed/28494776 http://dx.doi.org/10.1186/s13023-017-0636-y |
Ejemplares similares
-
Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials
por: Vrinten, Charlotte, et al.
Publicado: (2015) -
Myasthenia Gravis: Its Treatment by a Combination of Prostigmin and Glycine-Ephedrine Therapy
por: Macfarlane, J. W.
Publicado: (1937) -
Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
por: de Meel, R. H. P., et al.
Publicado: (2018) -
Clinical trials in myasthenia gravis
por: Mahmood, A., et al.
Publicado: (2023) -
Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature
por: de Meel, Robert H.P., et al.
Publicado: (2019)